Evommune licensed a drug that erases an immune protein to bypass JAK inhibitor warnings; Caldera added a TL1A bispecific from ...
The Drug That Ended 30 Years of “Undruggable”: Rasonque Posts $197.6 Million in Its First Five Weeks
Revolution Medicines’ Rasonque (daraxonrasib) posted $197.6M in its first five weeks after FDA approval -- doubling survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results